For Immediate Release
Chicago, IL – December 27, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. TSLA, Adobe Inc. ADBE, Merck & Co., Inc. MRK, Edwards Lifesciences Corporation EW and Norfolk Southern Corporation NSC.
– Zacks Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Tesla, Adobe and Merck
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Tesla, Adobe and Merck. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Tesla have outperformed the Zacks Domestic Automotive industry over the past year (+52.4% vs. +19.5%). The Zacks analyst believes that robust demand for Models 3 and Y has been buoying Tesla’s revenues. TSLA achieved record levels of production and deliveries, despite a chip crunch, in the third quarter of 2021.
Tesla has also started ramping up volumes of Models S and X. China, being the biggest EV market, means Tesla’s Shanghai factory is buoying its revenue prospects. Steadily increasing automotive as well as energy generation and storage revenues have also been boosting earnings prospects.
(You can read the full research report on Tesla here >>>)
Adobe shares have gained +12.7% in the year to date period against the Zacks Software industry’s gain of +39.1%; however, things seem to be improving. The Zacks analyst believes that Adobe’s Creative Cloud, Document Cloud and Adobe Experience Cloud products drove top-line growth in the fiscal fourth quarter.
Growth in emerging markets, robust online video creation demand, solid adoption of Acrobat and improving average revenue per user are some of the major tailwinds. Adobe’s dominant market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and strong Workfront momentum are likely to boost its prospects in the quarters ahead. Low end-market demand and high acquisition expenses remain as concerns though.
(You can read the full research report on Adobe here >>>)
Shares of Merck have gained +1.6% in the last six months against the Zacks Large Cap Pharmaceuticals industry’s gain of +18.2%, but things are likely to improve. The Zacks analyst believes that key drugs like Keytruda, Lynparza and Bridion have been driving Merck’s sales.
Continued uptake in lung cancer and increasing usage in other cancer indications have been driving Keytruda’s sales. Animal health and vaccine products remain as core growth drivers. Generic competition for several of Merck’s drugs as well as rising competitive pressure, primarily on the diabetes franchise, remain as major concerns though.
(You can read the full research report on Merck here >>>)
Other noteworthy reports we are featuring today include Edwards Lifesciences and Norfolk Southern Corp.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Norfolk Southern Corporation (NSC): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Adobe Inc. (ADBE): Free Stock Analysis Report
Tesla, Inc. (TSLA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
